Bioretec Ltd's Rights Issue Highlights Success
Bioretec Ltd, a leader in biodegradable orthopedic implants, has successfully completed a rights issue that has far exceeded expectations. This significant event showcases both the company's health and the strong support from investors, reaffirming confidence in Bioretec's innovative approaches in medical technology.
Overview of the Rights Offering
The rights issue drew immense interest, with a total of 7,658,836 new shares subscribed for, which represents an impressive 124.4% of the original offering of 6,156,618 new shares. This oversubscription demonstrates the robust demand for Bioretec's products and the enthusiasm of its stakeholders.
Subscription Breakdown
A substantial 4,882,744 new shares were successfully subscribed using subscription rights, accounting for about 79.3% of the total shares offered. The remaining shares were allocated from secondary subscriptions, ensuring that interested investors could still partake in this opportunity.
Financial Impact of the Offering
The gross proceeds from this offering are approximately EUR 9.2 million, which will play a vital role in funding Bioretec's ongoing projects and product developments. This financial boost will help the company maintain its position as a pioneer in the biodegradable implant market, aiming to revolutionize orthopedic surgery globally.
Increase in Share Capital
Following this offering, Bioretec will see its total number of shares increase from 24,626,474 to 30,783,092. This growth signifies a 20.0% increase in outstanding shares post-offering, reflecting the company's commitment to advancing its development and reaching new markets.
Upcoming Changes and Trading Information
Investors should note that the last day for trading interim shares on Nasdaq First North Growth Market Finland is approaching. Trading in the new shares is set to begin shortly after their registration with the Finnish Trade Register.
Adjustments to Stock Option Programs
In line with the rights issue, Bioretec's Board of Directors confirmed there will be adjustments made to the subscription prices in the company’s stock option programs. This decision aims to address any dilutive effects resulting from the new shares issued during the offering.
Investor and Legal Counsel Support
Bioretec has enlisted the expertise of Danske Bank A/S and DNB Carnegie Investment Bank AB as the Joint Global Coordinators. Their guidance has been instrumental in navigating this successful offering, along with the legal counsel from Krogerus Attorneys Ltd and Borenius Attorneys Ltd.
Bioretec's Mission and Market Reach
Bioretec prides itself on leading the way in developing biodegradable orthopedic solutions. With innovative products like the RemeOs™ line, they are positioned strategically to address the global orthopedic trauma market, which is valued at over USD 10 billion. The company's commitment to enhancing surgical outcomes makes it a game changer in the industry.
Frequently Asked Questions
What was the goal of Bioretec's rights issue?
The goal was to raise funds to support the company’s ongoing research and development of biodegradable orthopedic implants.
How many new shares were offered in the rights issue?
A total of 6,156,618 new shares were initially offered, which was exceeded significantly by subscriptions.
What are the anticipated benefits of the new RemeOs™ products?
The RemeOs™ products are designed for better absorption and replacement by bone, improving patient recovery and eliminating the need for removal surgeries.
What is Bioretec's market focus?
Bioretec primarily focuses on the orthopedic trauma and spine market, emphasizing the use of biodegradable materials for effective treatment solutions.
How will the funds from the rights issue be utilized?
Funds will be allocated towards further development of Bioretec’s innovative products and expansion into new markets.
